Addition of Clofarabine to TLI/ATG Conditioning: Impact on Immune Reconstitution and Clinical Outcomes,
Brett Glotzbecker(Dana-Farber Cancer Institute), David Avigan(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Jason Glass(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Thomas R. Spitzer(Harvard University), Jessica Bonhoff(Beth Israel Deaconess Medical Center), Karen K. Ballen(University of Virginia Health System), Carol Delaney(Beth Israel Deaconess Medical Center), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Caitlin McMahon(Beth Israel Deaconess Medical Center), Jamie Mortellite(Beth Israel Deaconess Medical Center), Katarina Luptakova(Tesaro (United States)), Baldev Vasir(Beth Israel Deaconess Medical Center), Katharine Conway(Beth Israel Deaconess Medical Center), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Nancy Giallombardo(Beth Israel Deaconess Medical Center), Eyal C. Attar(Memorial Sloan Kettering Cancer Center), Dina Stroopinsky(Beth Israel Deaconess Medical Center), Yi-Bin A. Chen(Harvard University), Maryann Stevenson(Beth Israel Deaconess Medical Center), Heidi Mills(Beth Israel Deaconess Medical Center), Stefanie O'Brien(Beth Israel Deaconess Medical Center), Jeffrey I. Zwicker(Memorial Sloan Kettering Cancer Center), James D. Levine(Beth Israel Deaconess Medical Center), Donna Fitzgerald(Beth Israel Deaconess Medical Center)
Cited by 0
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k